Clinical Trials Logo

Embolism clinical trials

View clinical trials related to Embolism.

Filter by:

NCT ID: NCT06362928 Not yet recruiting - Clinical trials for Pulmonary Embolism Acute

Safety and Effectiveness of the Akura Thrombectomy System in the Treatment of Acute Pulmonary Embolism

Start date: July 2024
Phase: N/A
Study type: Interventional

This study is a prospective, single-arm, non-randomized, interventional, multicenter feasibility study to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the Akura Thrombectomy System in subjects with acute pulmonary embolism (PE).

NCT ID: NCT06362746 Not yet recruiting - Pulmonary Embolism Clinical Trials

Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

Start date: May 15, 2024
Phase: Phase 3
Study type: Interventional

Objective: to evaluate the efficacy and safety of the non-immunogenic recombinant staphylokinase with its single bolus administration in comparison with placebo in normotensive patients with intermediate high-risk pulmonary embolism (PE)

NCT ID: NCT06362343 Recruiting - Pulmonary Embolism Clinical Trials

The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics

Start date: January 1, 2024
Phase:
Study type: Observational

1. Integrate pharmacokinetic-pharmacodynamic (PK-PD) modeling and pharmacogenomics techniques to develop a population PK-PD model, aiming to explore monitoring and dose guidance schemes for Direct Oral Anticoagulants (DOACs). 2. Investigate the factors influencing PK-PD of DOACs in the pulmonary embolism population, clarifying the correlation between genotype characteristics and clinical outcomes. 3. Explore the correlation between drug concentrations, coagulation indices, and clinical outcomes of DOACs, defining the indications for DOACs testing and the overall monitoring process.

NCT ID: NCT06360627 Recruiting - Lung Cancer Clinical Trials

Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT

Start date: February 20, 2023
Phase: N/A
Study type: Interventional

Evaluation of ultra low dose protocols and Iomeron 400 contrast in PCD-CT

NCT ID: NCT06357403 Not yet recruiting - Pulmonary Embolism Clinical Trials

Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients

AntiXa-ICU
Start date: May 2024
Phase:
Study type: Observational

The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and/or pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are: - What is the association between antiXa and VTE? - What is the association between antiXa and symptomatic, respectively incidental, VTE? - How is pharmacological anticoagulation with enoxaparin related to measured antiXa? - What is the association between antiXa and bleeding complications. - What is the incidence of venous thromboembolism in patients treated at an intensive care unit? - How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit/hospital.

NCT ID: NCT06348459 Recruiting - Pulmonary Embolism Clinical Trials

Registry of Catheter Intervention in Pulmonary Embolism

RiTEP
Start date: September 18, 2018
Phase:
Study type: Observational [Patient Registry]

Multicenter longitudinal observational ambispective (retrospective cases from 2014 and prospective from 2018 onwards) cohort study. The registry recruits a series of consecutive patients admitted for moderate-high risk or high-risk pulmonary embolism (according to 2019 European Society of Cardiology guidelines) treated invasively. This study aims to describe the acute management of the safety and effectiveness of different percutaneous interventions for acute pulmonary embolism.

NCT ID: NCT06320236 Recruiting - Pulmonary Embolism Clinical Trials

Emergency Medicine Pulmonary Embolism Testing Multicentre Study

EMPET
Start date: January 1, 2024
Phase:
Study type: Observational

It is important to diagnose pulmonary embolism in a timely manner to prevent death and long-term disability. More than half a million people (4-5% of emergency department patients) are tested for pulmonary embolism, although positive results are low. Imaging for PE testing exposes patients to radiation, is expensive, adds time to the emergency visit, and can lead to a false positive diagnoses. Existing protocols aimed at reducing unnecessary pulmonary embolism imaging are complex and seldom used by emergency physicians. Too many patients undergo unnecessary pulmonary embolism imaging. We have created a new tool (called Adjust-Unlikely) which could safely reduce pulmonary embolism imaging in Canada. Our research group composed of researchers, emergency physicians, and patients developed the Adjust-Unlikely clinical decision rule: a rule which has been customized for emergency physicians and emergency patients. Adjust-Unlikely is highly sensitive at the bedside, meaning there are very few false negative results. Our study aim is to prospectively validate Adjust-Unlikely pulmonary embolism testing in emergency patients with suspected pulmonary embolism.

NCT ID: NCT06312332 Not yet recruiting - Pulmonary Embolism Clinical Trials

Michigan Emergency Department Improvement Collaborative (MEDIC) Alert; Pulmonary Embolism (PE)

Start date: March 2024
Phase: N/A
Study type: Interventional

This study is a quality improvement project to evaluate health care management of pulmonary embolism (PE) patients. The researchers are testing an intervention to determine if it prevents unnecessary hospital admissions.

NCT ID: NCT06310018 Not yet recruiting - Pulmonary Embolism Clinical Trials

Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE

SONIC-PE
Start date: June 30, 2024
Phase: N/A
Study type: Interventional

SONIC-PE is a multicenter, prospective, single-arm study of 10 patients with bilateral PE treated with ultrasound-facilitated, catheter-directed lower-dose fibrinolysis (total dose 8 mg tPA given as 2 mg/hour/catheter over 2 hours) followed by 50 patients (total dose 6 mg tPA given as 3 mg/hour/catheter given over 1 hour) with the EKOS+™ system to determine its impact on the change in RV-to-LV diameter, refined Modified Miller Score, and distal pulmonary vascular blood volume as well as to assess International Society on Thrombosis and Haemostasis (ISTH) major bleeding.

NCT ID: NCT06309069 Not yet recruiting - Clinical trials for Calcified Cerebral Embolism

Calcified Cerebral Embolism: a Descriptive Study in a Large Single Center Cohort

CCE Cohorte
Start date: April 2024
Phase:
Study type: Observational

Calcified cerebral embolism (CCE) is a relatively rare but underdiagnosed cause of infarction. CCE diagnosis is made by CT. Radiological characteristics of CCE have been reported in small case series. The aim of this study was to describe clinical and radiological characteristics of CCE in a large number of patients, and to compare patients with different radiological CCE characteristics.